AstraZeneca Results Presentation Deck
Tagrisso and Imfinzi
Increased reimbursement and launches offsetting COVID-19 impact on diagnosis
Tagrisso: 13% growth to $5.0bn
Approvals/Reimbursements: 69/19 (adjuvant), 92/52 (1L), 92/68 (2L)
$m
1,400
1,200
1,000
800
600
400
200
0
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2019
2020
US Europe EROW EM
2021
• US +14%
FLAURA and ADAURA new patient
starts and DoT growth
2021 exit diagnosis rates for lung
10-15% below pre-pandemic levels
●
Europe +25% (Q4 +7%)
Increased reimbursement
EROW +14%
Japan +8%
• EM +6% (Q4 +23%)
China 1st-line volume growth
continues after NRDL
implementation
$m
700
600
500
400
300
200
100
Imfinzi: 16% growth to $2.4bn
Approvals/Reimbursements: 75/35 (NSCLC), 67/9 (ES-SCLC)
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2019
2020
US Europe EROW EM
2021
• US +5% (Q4 +10%)
●
Europe +25%
Growth from PACIFIC and CASPIAN
launches
• EROW +23%
Improving CRT rates and strong
CASPIAN demand driving growth
despite mandatory price
adjustment in Japan in August
• EM +68% (Q4 +44%)
Strong underlying demand
China destocking in Q4 2021
17 EROW= established rest of world; EM = emerging markets; 1L = first line; 2L = second line; DoT= duration of treatment; ES-SCLC = extensive-stage small cell lung cancer; CRT = chemoradiation therapy; NRDL = national
reimbursement drug list.
BView entire presentation